Pegfilgrastim & Eflapegrastim
Q2 2024 ASP Report
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
MARCH 2024
Aria analytics
Aria is dedicated to enhancing value for our members through cutting-edge analytics and business intelligence solutions. With this objective, our team has compiled a report to assist members in understanding the product landscape, visualizing ASP trends, and anticipating future ASPs for key products.
Our goal is to empower members with clear insights, enabling well-informed purchasing decisions and the development of sustainable, long-term strategies.
The content provided in this material is for informational purposes only and is not intended as legal advice or to replace a medical provider’s judgment. All information used in this material has been sourced from publicly available sources. Aria GPO “Aria” does not endorse or approve, assumes no responsibility for, and makes no representations nor warranties regarding, the content, accuracy or completeness of the information presented. Aria GPO does not own the intellectual property rights to any pharmaceutical product mentioned herein.
© 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Copyright
Table of contents
• Product comparison
• Average Sales Prices Q1 2024 & Q2 2024
• Reimbursement information for Q2 2024
• Historical ASPs
• Average Change of ASP
• WAC vs. Initial ASPs
• ASP Percent Change from WAC
• Aria ASP predictive model
The content provided in this material is for informational purposes only and is not intended as legal advice or to replace a medical provider’s judgment. All information used in this material has been sourced from publicly available sources. Aria GPO “Aria” does not endorse or approve, assumes no responsibility for, and makes no representations nor warranties regarding, the content, accuracy or completeness of the information presented. Aria GPO does not own the intellectual property rights to any pharmaceutical product mentioned herein.
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product comparison
Product Strength & Dosage Indication Cold Chain
Neulasta1 (Amgen)
Udenyca2 (Coherus)
Stimufend3 (Fresenius Kabi)
Nyvepria4 (Pfizer)
Ziextenzo5 (Sandoz)
Fylnetra6 (Amneal)
Rolvedon7 (Asserto)
Fulphila8 (Biocon)
Injection: Single-dose prefilled syringe 6mg/0.6mL
Injection: Single-dose prefilled syringe co-packaged with the on-body injector 6mg/0.6mL
Injection: Single-dose prefilled syringe 6mg/0.6mL
Injection: Single-dose prefilled autoinjector 6mg/0.6mL
Injection: Single-dose prefilled syringe 6mg/0.6mL
Injection: Single-dose prefilled syringe 6mg/0.6mL
Injection: Single-dose prefilled syringe 6mg/0.6mL
Injection: Single-dose prefilled syringe 6mg/0.6mL
Injection: Single-dose prefilled syringe 13.2mg/0.6mL
Injection: Single-dose prefilled syringe 6mg/0.6mL
1.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fdfe5d72-6b80-435a-afa4-c5d74dd852ce 2.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8c290ee-b699-4395-a596-1453d4a4b4eb 3.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b44bcb82-7e60-4dab-a658-115bdf5c053c 4.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99d30b99-2743-446b-98f3-0430bf4ea869
5.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7dada041-6528-4acf-809c-62d271538c9a 6.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eeadd641-573d-47fe-897a-61006e5f9e03 7.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e436115-62e7-4729-aeb0-ff78ea685206 8.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9bfc4d3e-6120-7fec-f1d6-0b3743752034
Decrease the incidence of infection in patients with cancer receiving Myelosuppressive Chemotherapy, Increase survival in patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome
Yes
Decrease the incidence of infection in patients with cancer receiving Myelosuppressive Chemotherapy
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Average Sales Prices Q1 2024 & Q2 2024
(Coherus) Fylnetra (Amneal)
(Assertio)
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product WAC Previous ASP New ASP % Change Avg % Change Biologic Neulasta (Amgen) $6,417.99 $573.71 $1,242.50 116.57% -3.42% Biosimilars Fulphila (Biocon) $2,087.50 $1,436.06 $1,893.89 31.88% -3.19% Nyvepria (Pfizer) $3,925.00 $714.10 $686.67 -3.84% -13.45% Udenyca (Coherus) $4,175.00 $1,430.81 $1,551.28 8.42% -4.58% Ziextenzo (Sandoz) $3,925.53 - - - -23.04% Fylnetra (Amneal) $2,500.00 $2,389.27 $2,341.23 -2.01% -2.34% Stimufend (Fresenius) $4,300.25 $3,909.62 $4,054.66 3.72% -0.92% Alternative Biologic Rolvedon (Assertio) $4,500.00 $3,695.88 $3,453.79 -6.55% -4.40% 116.57% 31.88% -3.84% 8.42% -2.01% 3.72% -6.55% $0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 $4,000 $4,500 Neulasta
Stimufend
ASP New ASP
(Amgen) Fulphila (Biocon) Nyvepria (Pfizer) Udenyca
(Fresenius) Rolvedon
ASP Change Previous
*Includes Medicare sequestration
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product Launch Date HCPCS WAC ASP Anticipated Medicare Reimbursement* Biologic Neulasta (Amgen) 2/28/2015 J2506 $6,417.99 $1,242.50 $1,295.98 Biosimilars Fulphila (Biocon) 7/31/2018 Q5108 $2,087.50 $1,893.89 $1,936.96 Nyvepria (Pfizer) 1/31/2021 Q5122 $3,925.00 $686.67 $773.49 Udenyca (Coherus) 1/31/2019 Q5111 $4,175.00 $1,551.28 $1,599.82 Ziextenzo (Sandoz) 12/31/2019 Q5210 $3,925.53 -Fylnetra (Amneal) 05/31/2023 Q5130 $2,500.00 $2,341.23 $2,377.13 Stimufend (Fresenius) 3/31/2023 Q5127 $4,300.25 $4,054.66 $4,063.14 Alternative Biologic Rolvedon (Assertio) 10/18/2022 J3590 $4,500.00 $3,453.79 $3,602.44
Reimbursement information for Q2 2024
Historical ASPs
Neulasta (Amgen) Fulphila (Biocon) Nyvepria (Pfizer) Udenyca (Coherus) Ziextenzo (Sandoz) Fylnetra (Amneal) Stimufend (Fresenius) Rolvedon (Assertio)
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
$0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 $4,000 $4,500 $5,000 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Average Change of ASP
This graph showcases the cumulative average change in the average sales price (ASP) for the Pegfilgrastim family, tracking changes from the launch of biosimilars to each quarter's ASP. It highlights the evolution of ASP over the product's lifecycle and the fluctuating rate of change, providing a concise overview of pricing dynamics.
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential. -16% -14% -12% -10% -8% -6% -4% -2% 0% 2% Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Neulasta (Amgen) Fulphila (Biocon) Nyvepria (Pfizer) Udenyca (Coherus) Fylnetra (Amneal) Stimufend (Fresenius) Rolvedon (Assertio)
WAC* vs. Initial ASPs
*Refers to the WAC when the first ASP was released
© 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Copyright
-25.4% 112.0% 3.0% 3.0% -3.0% -1.8% -3.8% -12.1% -25.3% 106.0% -3.9% 3.3% -6.6% -4.4% -9.1% -13.3% -21.5% 101.3% -13.0% -0.3% -8.9% -6.4% -5.7% -17.9% $0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 $4,000 $4,500 $5,000
Neulasta (Amgen) Fulphila (Biocon) Nyvepria (Pfizer) Udenyca (Coherus) Ziextenzo (Sandoz) Fylnetra (Amneal) Stimufend (Fresenius) Rolvedon (Assertio)
WAC First ASP Second ASP Third ASP
ASP Percent Change from WAC*
Neulasta (Amgen) Fulphila (Biocon) Nyvepria (Pfizer) Udenyca (Coherus) Ziextenzo (Sandoz) Fylnetra (Amneal) Stimufend (Fresenius) Rolvedon (Assertio)
*Refers to the WAC when the first ASP was released
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
-100% -80% -60% -40% -20% 0% 20% 40% 60% 80% Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Aria ASP predictive model
In line with Aria's goal to provide key insights to our members, our analytics team has developed a proprietary predictive ASP model for the Pegfilgrastim and Eflapegrastim product family.
Neulasta
Ziextenzo
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
$0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 $4,000 $4,500 $5,000 Q12019 Q22019 Q32019 Q42019 Q12020 Q22020 Q32020 Q42020 Q12021 Q22021 Q32021 Q42021 Q12022 Q22022 Q32022 Q42022 Q12023 Q22023 Q32023 Q42023 Q12024 Q22024Q32024Predicted
(Amgen) Fulphila (Biocon) Nyvepria (Pfizer) Udenyca (Coherus)
(Sandoz) Fylnetra (Amneal) Stimufend (Fresenius) Rolvedon (Assertio)
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential. Thank you. www.ariagpo.com info@ariagpo.com